Type 2 diabetes was associated with an increased need for pacemaker treatment compared with matched controls without diabetes (HR 1.65; 95% CI 1.60-1.69; P<0.0001).
Cohort (n=2,497,482)
Does type 2 diabetes increase the demand for pacemaker treatment compared to the general population?
Patients with type 2 diabetes have a significantly higher risk of requiring pacemaker implantation compared to matched controls without diabetes, with risk increasing with age, diabetes duration, and HbA1c.
Hazard Ratio: 1.65 (95% CI 1.6–1.69)
p-value: p=<0.0001
OBJECTIVE Patients with type 2 diabetes have an increased risk for cardiovascular disease, including arrhythmias. The prevalence of bradyarrhythmia and the subsequent need for treatment with pacemakers (PMs) is less well explored in a contemporary patient population. The current study explores 1) whether patients with type 2 diabetes have an increased demand for PM implantation compared with an age- and sex-matched control population without diabetes and 2) patient characteristics associated with an increased demand for receiving a PM. RESEARCH DESIGN AND METHODS In this population-matched registry study, a total of 416,247 patients with type 2 diabetes from the Swedish National Diabetes Registry and 2,081,235 age- and sex-matched control subjects selected from the general population were included between 1 January 1998 and 31 December 2012 and followed until 31 December 2013. Mean follow-up time was 7 years. Cox proportional hazards regression analyses were performed to estimate the demand of PM treatment and the factors identifying patients with such demand. RESULTS Type 2 diabetes was associated with an increased need of PM treatment (hazard ratio 1.65 95% CI 1.60–1.69; P 0.0001), which remained (1.56 1.51–1.60; P 0.0001) after adjustments for age, sex, educational level, marital status, country of birth, and coronary heart disease. Risk factors for receiving a PM included increasing age, HbA1c, BMI, diabetes duration, and lipid- and blood pressure–lowering medication. CONCLUSIONS The need for PM treatment is higher in patients with type 2 diabetes than in matched population-based control subjects. Age, diabetes duration, and HbA1c seem to be risk factors for PM treatment.
Rautio et al. (Fri,) conducted a cohort in Type 2 diabetes (n=2,497,482). Type 2 diabetes vs. Age- and sex-matched control subjects without diabetes was evaluated on Need of pacemaker treatment (HR 1.65, 95% CI 1.60-1.69, p=<0.0001). Type 2 diabetes was associated with an increased need for pacemaker treatment compared with matched controls without diabetes (HR 1.65; 95% CI 1.60-1.69; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: